Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Glioma-associated antigens associated with prolonged survival in a phase I study of ICT-107 for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results